Patent ID: 7384925

Claim:
A method for treating a vascular proliferative disorder in a host comprising administering to a host an effective amount of the compound of the formula I: or a pharmaceutically acceptable salt or hydrate thereof wherein: R 1 , R 4 , and R 5 are each independently H, OH, lower alkoxy, NH 2 , NO 2 , N 3 , NHR 6 , halogen, or a phosphate ester salt moiety of the general formula (—OP(O)O − M + ) 2 ,(—OP(O)(OR 9 )(O − M + ), or —OPO 3 R 7 R 8 ; R 2 is H, OH, lower alkoxy, NH 2 , NO 2 , NHR 6 , or a phosphate ester salt moiety of the general formula (—O—P(O)(O − M + ) 2 , (—OP(O)(OR 9 )(O − M + ), or —OPO 3 R 7 R 8 , wherein NH 2 or OH may form a ring with R 1 ; R 3 is H, lower alkoxy, or a phosphate ester salt moiety of the general formula (—OP(O)(O − M + ) 2 , (—OP(O)(OR 9 )(O − M + ), or —OPO 3 R 7 R 8 ; R 6 is acylamino group; R 7 is ammonium salt (NH 4 + ); R 8 is lower alkyl, cycloalkyl, or aryl; R 9 is alkyl, branched alkyl, benzyl, or aryl; and M is a metal cation or salt, provided that when R 1 , R 4 , and R 5 are H, R 2 is H, lower alkoxy, NH 2 , NO 2 , NHR 6 , or a phosphate ester salt moiety of the general formula (—OP(O)(OR 9 )(O − M + ) or —OPO 3 R 7 R 8 ; and provided that when R 1 , R 2 , and R 5 are H, R 4 is H, lower alkoxy, NH 2 , NO 2 , NHR 6 , or a phosphate ester salt moiety of the general formula (—OP(O)(OR 9 )(O − M + ) or —OPO 3 R 7 R 8 , wherein said vascular proliferative disorder is selected from wet macular degeneration, diabetic retinopathy, retinopathy of prematurity, restenosis, and a cancer selected from leukemia, lung, colon, thyroid, melanoma, ovarian, renal, prostate, and breast cancer.